Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Silo Pharma (SILO) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Silo Pharma (SILO) over the last 11 years, with Q3 2025 value amounting to 6150.66%.

  • Silo Pharma's EBITDA Margin fell 10630500.0% to 6150.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 7052.84%, marking a year-over-year decrease of 18339600.0%. This contributed to the annual value of 6080.6% for FY2024, which is 9394000.0% down from last year.
  • Latest data reveals that Silo Pharma reported EBITDA Margin of 6150.66% as of Q3 2025, which was down 10630500.0% from 6687.56% recorded in Q2 2025.
  • Silo Pharma's 5-year EBITDA Margin high stood at 574643.9% for Q4 2021, and its period low was 9697.09% during Q4 2024.
  • Moreover, its 5-year median value for EBITDA Margin was 5087.62% (2024), whereas its average is 30827.47%.
  • In the last 5 years, Silo Pharma's EBITDA Margin soared by 2000000000bps in 2021 and then plummeted by 2000000000bps in 2022.
  • Silo Pharma's EBITDA Margin (Quarter) stood at 574643.9% in 2021, then tumbled by -102bps to 9224.63% in 2022, then soared by 32bps to 6250.31% in 2023, then crashed by -55bps to 9697.09% in 2024, then skyrocketed by 37bps to 6150.66% in 2025.
  • Its last three reported values are 6150.66% in Q3 2025, 6687.56% for Q2 2025, and 5675.98% during Q1 2025.